Drupacine as a potent SARS-CoV-2 replication inhibitor in vitro
Year: 2024
Type: article
Abstract: enzymatic assays revealed that the inhibition could not be attributed to conventional antiviral targets, such as the viral non-structural proteins nsp5 (MPro) or nsp12 (RdRp). In conclusion, our findings position drupacine as a promising antiviral candidate against SARS-CoV-2, providing a novel scaffold for developing anti-coronavirus disease 2019 therapeutics. Further investigation is required to pinpoint its precise target and mechanism of action.
Source: Biosafety and Health
Authors: Chen Yang, Yanying Yu, Qi Peng, Jingwei Song, Bo Sun, Yi Shi, Qiang Ding
Language: English
Subfield: Infectious Diseases
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,500
Awards: G2491921409, G2839098677
OpenAlex ID: W4402197967